Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC “Rarely” Lacks Targets In Health Care Ads – Consumer Protection Chief

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission's consumer protection chief says although the FTC's budget for fiscal 2008 of $240.2 million is a fraction of FDA's, the commission has no shortage of enforcement activity related to health care products

You may also be interested in...



“Smiling Bob” firm convicted

A federal jury on Feb. 22 convicts four executives of Cincinnati-based Berkeley Premium Nutraceuticals, marketer of Enzyte "male enhancement" supplements, of conspiracy and fraud on criminal charges of money laundering, fraud and obstruction of justice. A federal grand jury indicted the firm, Berkeley's President Steve Warshak, his mother and five additional defendants and co-conspirators on a total of 112 criminal charges in September 2006 (1"The Tan Sheet" Sept. 25, 2006, In Brief). The trial jury in the U.S. District Court for Southern Ohio also found on Feb. 26 that Berkeley, Warshak, his mother and TCI Media, another company owned by Warshak, should forfeit to the U.S. more than $33 million in assets that were proceeds of the crimes. In addition, the jury convicted Paul J. Kellogg and Steven P. Pugh. Berkeley also settled with six states in March 2006 for $2.5 million (2"The Tan Sheet" March 6, 2006, p. 8)...

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

Innovo Incontinence Device Goes OTC In US, Labeled To Be Worn For 30 Minutes

Atlantic Therapeutics estimates that one in three women are incontinent, but 60% don’t ask their health care providers about treatment, a statistic that supports offering Innovo OTC less than two years after it launched Rx in the US.

Topics

UsernamePublicRestriction

Register

PS101502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel